Navigation Links
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
Date:5/27/2009

AMSTERDAM, May 28 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the European Medicines Agency has granted Orphan Drug Designation to AMT's gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP).

Orphan Drug Designation for AIP entitles AMT to ten year market exclusivity in Europe following marketing approval for AMT-021 if this product candidate is the first new drug with a major medical benefit receiving marketing approval for the European Union. The designation also provides for special benefits, including research support, eligibility for protocol assistance and possible exemptions or reductions in certain regulatory fees during development or at the time of application for marketing approval.

"We are proud to have received this Orphan Drug Designation for the treatment of acute intermittent porphyria," said Sander van Deventer, Chief Executive Officer of AMT. "This designation is an important step in the development of a treatment for this seriously debilitating and potentially lethal disease."

About Acute Intermittent Porphyria

Acute intermittent porphyria is a rare genetic disease in which mutations in the PBGD gene result in insufficient activity of a protein necessary for the synthesis of heme. This leads to an accumulation of toxic intermediate metabolites resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric, neurologic illnesses, and muscular weakness. Long-term consequences may be irreversible nerve damage, liver cancer and kidney failure. Acute porphyric attacks can be life-threatening.

AIP affects 1 per 10.000 people in the European Union.

Currently available therapies do not prevent the symptoms and consequences of acute porphyric attacks. AMT has demonstrated that its prod
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014  Grammy Award-winner Bruce Hornsby ... of philanthropists, athletes, actors, and musicians during the 10 ... 19 at the Mandarin Oriental Hotel in ... will honor six individuals who embody the values of ... bestow its highest honor, the Spirit of an Active ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... 2014 Imago BioSciences, Inc., a biotech ... million Series A financing led by Clarus Ventures ... team of accomplished investment and operating professionals dedicated ... round include Frazier Healthcare, Amgen Ventures, and Merck ... and Frazier Healthcare will join the company,s board ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... Johnson & Johnson, including the Palmaz-NIR suit. All ... arena. In connection with the settlement, Boston Scientific ... & Johnson. The settlement payment is within Boston ...
... MUMBAI, India, Sept. 29 Pharmaceutical Major, Lupin Ltd. announced ... 43 mg and 130 mg). Lupin acquired the product ... of the U.S. Bankruptcy Court. Antara recorded net sales ... 2008). Lupin paid $ 38.61 million for the product ...
Cached Medicine Technology:Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 2Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 3Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 4Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:10/31/2014)... 2014 (HealthDay News) -- Access to generic hormone therapy ... stick with their drug treatment, a new study found. ... hormone receptor-positive breast cancer can reduce recurrence by up ... associate professor of epidemiology at Columbia University Medical Center ... release. "However, work by our group and ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... Professor Elly Tanaka and her research group at the ... of Excellence at the TU Dresden (CRTD) demonstrated for ... piece of spinal cord in three dimensions from mouse ... interneurons and dorsal interneurons along the dorsal/ventral axis was ... American journal " Stem Cell Reports " on ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... Residents to Eat Right, Move More and ... Milk Their Diets, ST. ... and downs of different fad diets -- which seem to go in and ... out of three Americans -- including twenty-five percent of St.,Louis residents -- remain ...
... The Blue Cross Blue Shield of Michigan,Foundation has won ... Program. The awards, given by the Council on Foundations ... awareness of foundations and corporate giving programs. The,awards will ... Council on,Foundations on Monday, May 5, 2008 in Maryland., ...
... National Academy of Sciences of the United States has ... a member of this prestigious organization of scientists and ... in recognition of his distinguished and continuing achievements in ... has had a key role in a range of ...
... Universitys Lane Center for Computational Biology have discovered ... an automated method for analyzing cell cultures and ... online in the Journal of Machine Learning Research, ... analysis of the microscopic images produced by todays ...
... aims to educate patients on best ways to get condition ... Have asthma or think you might? Then May is the ... breathing disease. , Free asthma screenings are scheduled to be ... of National Asthma and Allergy Awareness Month. The American College ...
... - LMS Medical Systems (TSX: LMZ,AMEX: LMZ), a ... safety software system for obstetrics, today announced that ... the Company,s common,shares from Amex., The decision ... to,streamline operations and control costs in order to ...
Cached Medicine News:Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Blue Cross Blue Shield of Michigan Foundation Wins Three National Awards for Communications Excellence from Council on Foundations 2Health News:US honor for professor Jerry Adams 2Health News:Carnegie Mellon technique accelerates biological image analysis 2Health News:Free Asthma Screenings Offered in May 2Health News:LMS to delist from Amex 2
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Medicine Products: